Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of Linsitinib in Active Moderate to Severe Thyroid Eye Disease
2021-005000-36Phase 2Active
- Sponsor
- Sling Therapeutics, Inc.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of linsitinib in Graves Orbitopathy (GO) (3 arms), sponsored by Sling Therapeutics, Inc. Primary endpoint: Proptosis responder rate at Week 24. Started Mar 2022; status: active.
02
Drugs
linsitinib
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2021-005000-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005000-36.